<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31322417</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1535-4970</ISSN><JournalIssue CitedMedium="Internet"><Volume>200</Volume><Issue>12</Issue><PubDate><Year>2019</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>American journal of respiratory and critical care medicine</Title><ISOAbbreviation>Am J Respir Crit Care Med</ISOAbbreviation></Journal><ArticleTitle>Classifying Patients with Amyotrophic Lateral Sclerosis by Changes in FVC. A Group-based Trajectory Analysis.</ArticleTitle><Pagination><StartPage>1513</StartPage><EndPage>1521</EndPage><MedlinePgn>1513-1521</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1164/rccm.201902-0344OC</ELocationID><Abstract><AbstractText><b>Rationale:</b> A model for stratifying progression of respiratory muscle weakness in amyotrophic lateral sclerosis (ALS) would identify disease mechanisms and phenotypes suitable for future investigations. This study sought to categorize progression of FVC after presentation to an outpatient ALS clinic.<b>Objectives:</b> To identify clinical phenotypes of ALS respiratory progression based on FVC trajectories over time.<b>Methods:</b> We derived a group-based trajectory model from a single-center cohort of 837 patients with ALS who presented between 2006 and 2015. We applied our model to the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database with 7,461 patients with ALS. Baseline characteristics at first visit were used as predictors of trajectory group membership. The primary outcome was trajectory of FVC over time in months.<b>Measurements and Main Results:</b> We found three trajectories of FVC over time, termed "stable low," "rapid progressor," and "slow progressor." Compared with the slow progressors, the rapid progressors had shorter diagnosis delay, more bulbar-onset disease, and a lower ALS Functional Rating Scale-Revised (ALSFRS-R) total score at baseline. The stable low group had a shorter diagnosis delay, lower body mass index, more bulbar-onset disease, lower ALSFRS-R total score, and were more likely to have an ALSFRS-R orthopnea score lower than 4 compared with the slow progressors. We found that projected group membership predicted respiratory insufficiency in the PRO-ACT cohort (concordance statistic&#x2009;=&#x2009;0.78, 95% CI, 0.76-0.79).<b>Conclusions:</b> We derived a group-based trajectory model for FVC progression in ALS, which validated against the outcome of respiratory insufficiency in an external cohort. Future studies may focus on patients predicted to be rapid progressors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ackrivo</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansen-Flaschen</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Bobby L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wileyto</LastName><ForeName>E Paul</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>Center for Clinical Epidemiology and Biostatistics, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwab</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elman</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawut</LastName><ForeName>Steven M</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000-0001-7896-0608</Identifier><AffiliationInfo><Affiliation>Department of Medicine.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Clinical Epidemiology and Biostatistics, and.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K24 HL103844</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 HL144145</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG032953</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Respir Crit Care Med</MedlineTA><NlmUniqueID>9421642</NlmUniqueID><ISSNLinking>1073-449X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Am J Respir Crit Care Med. 2019 Dec 15;200(12):1461-1462</RefSource><PMID Version="1">31381864</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012131" MajorTopicYN="N">Respiratory Insufficiency</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014797" MajorTopicYN="N">Vital Capacity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">group-based trajectory modeling</Keyword><Keyword MajorTopicYN="N">prediction modeling</Keyword><Keyword MajorTopicYN="N">respiratory failure</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31322417</ArticleId><ArticleId IdType="pmc">PMC6909832</ArticleId><ArticleId IdType="doi">10.1164/rccm.201902-0344OC</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai C-P, Chang B-H, Lee CT-C. Underlying cause and place of death among patients with amyotrophic lateral sclerosis in Taiwan: a population-based study, 2003-2008. J Epidemiol. 2013;23:424&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3834279</ArticleId><ArticleId IdType="pubmed">23933623</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol. 2006;5:140&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">16426990</ArticleId></ArticleIdList></Reference><Reference><Citation>Czaplinski A, Yen AA, Appel SH. Amyotrophic lateral sclerosis: early predictors of prolonged survival. J Neurol. 2006;253:1428&#x2013;1436.</Citation><ArticleIdList><ArticleId IdType="pubmed">16773270</ArticleId></ArticleIdList></Reference><Reference><Citation>Czaplinski A, Yen AA, Appel SH. Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry. 2006;77:390&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2077717</ArticleId><ArticleId IdType="pubmed">16484652</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng H-J, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17:423&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL.the World Federation of Neurology Research Group on Motor Neuron Diseases El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis Amyotroph Lateral Scler Other Motor Neuron Disord 20001293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagin DS. Group-based trajectory modeling: an overview. Ann Nutr Metab. 2014;65:205&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">25413659</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagin DS, Odgers CL. Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol. 2010;6:109&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">20192788</ArticleId></ArticleIdList></Reference><Reference><Citation>Dudley WN, Wickham R, Coombs N. An introduction to survival statistics: Kaplan-Meier analysis. J Adv Pract Oncol. 2016;7:91&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5045282</ArticleId><ArticleId IdType="pubmed">27713848</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnus T, Beck M, Giess R, Puls I, Naumann M, Toyka KV. Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve. 2002;25:709&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">11994965</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffman PL, Belsh JM. Pulmonary function at diagnosis of amyotrophic lateral sclerosis: rate of deterioration. Chest. 1993;103:508&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pubmed">8432145</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo A, Moglia C, Lunetta C, Marinou K, Ticozzi N, Ferrante GD, et al. Factors predicting survival in ALS: a multicenter Italian study. J Neurol. 2017;264:54&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">27778156</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavelou P, Blanquet M, Peyrol F, Ouchchane L, Gerbaud L. Rates of progression of weight and forced vital capacity as relevant measurement to adapt amyotrophic lateral sclerosis management for patient Result of a French multicentre cohort survey. J Neurol Sci. 2013;331:126&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">23809193</ArticleId></ArticleIdList></Reference><Reference><Citation>Elamin M, Bede P, Montuschi A, Pender N, Chi&#xf2; A, Hardiman O. Predicting prognosis in amyotrophic lateral sclerosis: a simple algorithm. J Neurol. 2015;262:1447&#x2013;1454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4469087</ArticleId><ArticleId IdType="pubmed">25860344</ArticleId></ArticleIdList></Reference><Reference><Citation>Esquinas Rodriguez AM, Paladini L, Vianello A. Respiratory function deterioration and the effect of non-invasive mechanical ventilation in amyotrophic lateral sclerosis: the crucial importance of bulbar muscle involvement. Eur J Neurol. 2013;20:e65.</Citation><ArticleIdList><ArticleId IdType="pubmed">23577607</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xfc;ffner R, Zach N, Norel R, Hawe J, Schoenfeld D, Wang L, et al. Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. Nat Biotechnol. 2015;33:51&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">25362243</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackrivo J, Hansen-Flaschen J, Wileyto EP, Schwab RJ, Elman L, Kawut SM. Development of a prognostic model of respiratory insufficiency or death in amyotrophic lateral sclerosis. Eur Respir J. 2019;53:1802237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6684229</ArticleId><ArticleId IdType="pubmed">30728207</ArticleId></ArticleIdList></Reference><Reference><Citation>Du W, Cheung H, Goldberg I, Thambisetty M, Becker K, Johnson CA. A longitudinal support vector regression for prediction of ALS score. IEEE Int Conf Bioinform Biomed Workshops. 2015;2015:1586&#x2013;1590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4814169</ArticleId><ArticleId IdType="pubmed">27042700</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechtzin N, Wiener CM, Shade DM, Clawson L, Diette GB. Spirometry in the supine position improves the detection of diaphragmatic weakness in patients with amyotrophic lateral sclerosis. Chest. 2002;121:436&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">11834654</ArticleId></ArticleIdList></Reference><Reference><Citation>Polkey MI, Lyall RA, Yang K, Johnson E, Leigh PN, Moxham J. Respiratory muscle strength as a predictive biomarker for survival in amyotrophic lateral sclerosis. Am J Respir Crit Care Med. 2017;195:86&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5214920</ArticleId><ArticleId IdType="pubmed">27494149</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>